Ductal carcinoma in situ (DCIS) now represents 20–25% of all ‘breast cancers’ consequent
upon detection by population-based breast cancer screening programmes. Currently, all …

With the widespread adoption of population-based breast cancer screening, ductal carcinoma
in situ (DCIS) has come to represent 20–25% of all breast neoplastic lesions diagnosed. …

We performed a systematic review with meta-analyses to summarize current knowledge on
prognostic factors for invasive disease after a diagnosis of ductal carcinoma in situ (DCIS). …

Extracellular vesicles (EVs) are a potential source of disease-associated biomarkers for
diagnosis. In breast cancer, comprehensive analyses of EVs could yield robust and reliable …

Ductal carcinoma in situ (DCIS) is the most common form of preinvasive breast cancer and,
despite treatment, a small fraction (5–10%) of DCIS patients develop subsequent invasive …

Background Genetic variants in 15q25 have been identified as potential risk markers for lung
cancer (LC), but controversy exists as to whether this is a direct association, or whether the …

Invasive lobular carcinoma (ILC) has been reported to be less responsive to neoadjuvant
chemotherapy (NAC) than invasive ductal carcinoma (IDC). We sought to determine whether …

Patients with primary solid malignancies frequently exhibit signs of systemic inflammation.
Notably, elevated levels of neutrophils and their associated soluble mediators are regularly …

Introduction BRCA-mutated breast cancer cells lack the DNA-repair mechanism homologous
recombination that is required for error-free DNA double-strand break (DSB) repair. …

The topoisomerase II poisons doxorubicin and etoposide constitute longstanding cornerstones
of chemotherapy. Despite their extensive clinical use, many patients do not respond to …